Radiofrequency ablation eliminates nondysplastic BE

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

Radiofrequency ablation (RA) is effective for the complete eradication of nondysplastic Barrett’s esophagus (BE), according to researchers from the Academic Medical Center in Amsterdam.

ABSTRACT: Studies finds RA, with or without prior endoscopic resection, proves safe for removal of Barrett’s esophagus and associated neoplasia.

Radiofrequency ablation (RA) is effective for the complete eradication of nondysplastic Barrett’s esophagus (BE), according to researchers from the Academic Medical Center in Amsterdam.

 

Roos E. Pouw, MD, and colleagues enrolled 44 patients who had BE (median of 7 cm) with early neoplasia. Visible lesions were endoscopically resected. Circumferential and focal ablation was repeated every 2 months until the entire Barrett epithelium was eradicated (Journal of Gastrointestinal Surgery online, August 13, 2008).

 

Among 31 patients, 16 first underwent endoscopic resection for early cancer, 12 had high-grade dysplasia, and 3 displayed low-grade dysplasia. After resection, the worst remaining histology was high-grade in 32 cases, low-grade in 10 cases, and 2 without dysplasia.

 

Post-ablation, complete histological eradication of all dysplasia and intestinal metaplasia was achieved in 43 patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content